Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
30 Apr 24
ARS
2023 FY
Annual report to shareholders
20 Mar 24
DEF 14A
Definitive proxy
20 Mar 24
PRE 14A
Preliminary proxy
8 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Strengthens financial flexibility to support the Company’s continued growth
2 Jan 24
8-K
Changes in Registrant's Certifying Accountant
18 Dec 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2 Nov 23
8-K
Other Events
11 Sep 23
8-K
Entry into a Material Definitive Agreement
1 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
3 Aug 23
S-8
Registration of securities for employees
9 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
8-K
Departure of Directors or Certain Officers
1 May 23
ARS
2022 FY
Annual report to shareholders
21 Mar 23
DEF 14A
Definitive proxy
21 Mar 23
F-6EF
Automatic registration for ADRs (foreign)
7 Mar 23
S-3ASR
Automatic shelf registration
7 Mar 23
10-K
2022 FY
Annual report
7 Mar 23
8-K
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
7 Mar 23
8-K
Regulation FD Disclosure
20 Dec 22
S-8
Registration of securities for employees
15 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
9 Nov 22
8-K
Entry into a Material Definitive Agreement
17 Oct 22
8-K
Other Events
11 Aug 22
424B5
Prospectus supplement for primary offering
11 Aug 22
8-K
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
9 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
424B5
Prospectus supplement for primary offering
9 Aug 22
10-Q
2022 Q1
Quarterly report
3 May 22
8-K
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
3 May 22
8-K
Submission of Matters to a Vote of Security Holders
29 Apr 22
8-K
Entry into a Material Definitive Agreement
30 Mar 22
DEF 14A
Definitive proxy
22 Mar 22
Latest ownership filings
4
Mark W Hahn
3 May 24
4
Kathleen A. Rickard
3 May 24
4
DAVID ZACCARDELLI
3 May 24
4
Vikas Sinha
30 Apr 24
4
Martin Edwards
30 Apr 24
4
Anders Ullman
30 Apr 24
4
DAVID R EBSWORTH
30 Apr 24
4
CHRISTINA ACKERMANN
30 Apr 24
4
MAHENDRA SHAH
30 Apr 24
4
Kenneth Cunningham
30 Apr 24
4
James Aloysius Brady
30 Apr 24
4
Lisa Deschamps
30 Apr 24
4
Andrew Fisher
2 Apr 24
144
Notice of proposed sale of securities
12 Mar 24
3
Andrew Fisher
7 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
FMR LLC
9 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
4
DAVID ZACCARDELLI
5 Feb 24
4
Kathleen A. Rickard
5 Feb 24
4
Claire Poll
5 Feb 24
4
Mark W Hahn
5 Feb 24
144
Notice of proposed sale of securities
5 Feb 24
4
Michael Austwick
2 Feb 24
3
Michael Austwick
2 Feb 24
4
Martin Edwards
22 Nov 23
4
DAVID R EBSWORTH
8 Nov 23
4
Kathleen A. Rickard
3 Nov 23
4
Claire Poll
3 Nov 23
4
DAVID ZACCARDELLI
3 Nov 23
4
Mark W Hahn
3 Nov 23
144
Notice of proposed sale of securities
3 Nov 23
4
DAVID ZACCARDELLI
24 Oct 23
4
Kathleen A. Rickard
24 Oct 23
4
Claire Poll
24 Oct 23
4
Mark W Hahn
24 Oct 23
4
CHRISTINA ACKERMANN
5 Sep 23
3
CHRISTINA ACKERMANN
5 Sep 23